The global cyclobenzaprine market is anticipated to grow at a significant CAGR of 4.2% during the forecast period. The global expansion of this market is being driven by a high prevalence rate of chronic pain, such as low back pain and osteoarthritis, among patients. As per the information provided by the US Department of Health & Human Services in 2019, around 20.4% of adults had chronic pain among which nearly 7.4% of adults suffered from high-impact chronic pain that frequently limited life or work activities. Through effective utilization of Cyclobenzaprine which operates on skeletal muscles by competing with magnesium, leading to supports the reduction of aberrant muscular contractions and thus spasms. Additionally, it provides pain treatment for arthritis, fibromyalgia, and other medical problems such as cervical spondylosis, bursitis, and others. The primary ingredient in the medication is cyclobenzaprine hydrochloride, which enhances providing relief pain by blocking nerve signals between the brain and muscles. 

Impact of COVID-19 Pandemic on Global Cyclobenzaprine Market

A significant rise in the rates of back and neck discomfort had been observed due to the large number of people working from home during the COVID-19 Pandemic. Changes in sitting position, uncomfortable posture, lack of an ergonomic set-up, prolonged sitting, and other factors are all possible reasons. One of the key factors is a growing reliance on screens for work or to stay connected with family members. Due to all such reasons, there was an increase in demand for cyclobenzaprine drugs.  Along with this cyclobenzaprine was also used for COVID-19 Patients. 

Segmental Outlook

The global cyclobenzaprine market is segmented based on type and application. Based on the type, the market is segmented into purity:98%-99% and purity:99%. Based on the application, the market is sub-segmented into the relieve muscle spasms and fibromyalgia treatment. Among type, the purity:98%-99% segment is propelling the market growth forward. Purity:98%-99% denotes the percentage of cyclobenzaprine in a product. In general, cyclobenzaprine medications that contain 98-99% pure cyclobenzaprine are regarded as good grade and effective at relieving muscle spasms. Purity:98-99% cyclobenzaprine is a kind of cyclobenzaprine used to treat muscle spasms and fibromyalgia. 

Global Cyclobenzaprine Market Share by Application, 2021 (%)

The Relieve Muscle Spasms Segment Hold a Prominent Share in the Global Cyclobenzaprine Market

The relieve muscle spasms segment holds a significant market share and is anticipated to grow prominently during the forecast period in the global cyclobenzaprine market in the application segment. Tension, stress, overuse, and small injuries are the most common causes of muscular pain. Cyclobenzaprine is used to treat muscle spasms as it relaxes muscles and reduces discomfort by inhibiting nerve signals. Muscle spasms caused by acute, painful musculoskeletal problems are treated with cyclobenzaprine. The drug works by reducing the release of particular molecules that induce muscular discomfort and swelling.

Regional Outlooks

The global cyclobenzaprine market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.

Global Cyclobenzaprine Market Growth, by Region 2022-2028

The Asia-Pacific Region Expected to Hold Considerable Share in the Global Cyclobenzaprine Market

The Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the cyclobenzaprine market. The expansion of the geriatric population, rising disposable income, rising prevalence rates for chronic pain conditions such as arthritis among adults and aged 60 years or older. Additionally, a continuous rise in healthcare expenditure in many countries, including India and China, can all be attributed to this region's growth. 

Market Players Outlook

The major companies serving the global cyclobenzaprine market include Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Polpharma S.A., Admiron Life Sciences Pvt. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. In March 2019. TWi Pharmaceuticals, Inc., had announced the launch of Cyclobenzaprine HCL ER Capsules which is a generic version of Teva’s Amirx (cyclobenzaprine) extended-release capsules. Cyclobenzaprine HCL ER Capsules are used to treat muscle spasms caused by acute, painful musculoskeletal problems in addition to rest and physical therapy.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cyclobenzaprine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.